Elicio Therapeutics, Inc. (ELTX): Submission of Matters to a Vote of Security Holders

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On November 12, 2026, Elicio Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two

Event · Shareholder vote
Original reporting
Published Nov 13, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ELTX
Neutral
high confidence
Mentioned
$ELTX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ELTXNeutralLow
01

Why it matters

The filing confirms routine governance actions with no new strategic or financial announcements.

02

Market read

Minimal; the market likely already anticipated the governance vote.

03

What to watch

Potential future board composition changes, but not evident from this filing.

Relevance 6/10Novelty 4/10Timing: same day filing

Background

Elicio Therapeutics filed an 8‑K detailing the results of its 2026 annual shareholder meeting, including election of three Class III directors and ratification of Baker Tilly US as auditor.

Company-level read

Ticker impact

$ELTXNeutralHigh confidence
Context

SEC Form 8‑K reports the annual meeting vote on directors and auditor selection for Elicio Therapeutics.

Expected impact

neutral as the market has likely priced the governance outcomes.

Evidence & confidence

The filing is a standard disclosure of shareholder votes; no material change to operations or capital structure.

Market effects

None; governance matters are company‑specific.

None

None

Counterpoint

Unlikely any short‑term price move; focus on longer‑term fundamentals.

Key entities

  • Elicio Therapeutics, Inc.

    Biopharma company reporting its annual meeting outcomes.

  • Baker Tilly US, LLP

    Selected as the independent registered public accounting firm.

Related articles

$ELTXHigh

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and patients without prior radiation, enabling a

$ELTXHighAI 8/10

Elicio’s pancreatic cancer vaccine misses primary endpoint

Elicio Therapeutics (ELTX) reported that its Phase 2 study of camupepimut for pancreatic cancer did not meet the primary endpoint of disease-free survival. The study had a hazard ratio of 0.85, missing the target. Subgroup analyses showed potential benefits in patients without baseline ctDNA positivity. The company plans to discuss findings with the FDA for a potential Phase 3 study.

$ELTXMedAI 9/10

99% of evaluable treated patients showed immune responses to a cancer mutation. The trial missed its main goal.

Elicio Therapeutics (ELTX) reported Phase 2 trial results for camupepimut (ELI-002 7P) in pancreatic cancer, missing the primary DFS endpoint but showing favorable trends in subgroups. Key findings: 99% of patients showed immune responses, and DFS improvements were observed in ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients. The company plans to discuss Phase 3 study design with the FDA.

$ELTXLow

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a